{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-001557","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2022-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.025541+00:00","generated_at":"2026-06-27T17:20:05.128504+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immix Biopharma announces positive interim safety data: 100% IMX-110 treatment cycle completion in Phase 1b/2a trial","bullets":["100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.","Historical comparators for approved soft tissue sarcoma drugs show 43-67% completion rates (Demetri et al., 2015; Schöffski et al., 2016).","IMX-110 has FDA Orphan Drug Designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma.","Immix Biopharma (NASDAQ: IMMX) is developing IMX-110 as monotherapy for soft tissue sarcoma, a $3B market targeting $6.5B by 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-001557","json":"https://secwatch.observer/filing/0001493152-22-001557.json","markdown":"https://secwatch.observer/filing/0001493152-22-001557.md","text":"https://secwatch.observer/filing/0001493152-22-001557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222001557/0001493152-22-001557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222001557/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:20:05.128504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}